Faculty Collaboration Database

Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacother 2001 Jun;2(6):1009-13

Date

10/05/2001

Pubmed ID

11585003

DOI

10.1517/14656566.2.6.1009

Scopus ID

2-s2.0-0034871074 (requires institutional sign-in at Scopus site)   22 Citations

Abstract

The propensity of patients with carcinoma in situ (CIS) of the bladder to progress to invasive and metastatic disease is clearly established. Today, the standard therapy in treating patients with CIS of the bladder is intravesical bacillus Calmette-Guerin (BCG). Nevertheless, patients who fail intravesical BCG have few viable options except to undergo a radical cystectomy. Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a new semisynthetic derivative of the anthracycline antibiotic doxorubicin that has been shown to benefit patients with BCG-refractory CIS of the bladder. Intravesical instillation of valrubicin is well-tolerated, safe and can be durable. Early non-randomised studies show promise and the current utilisation of this drug is limited to patients with BCG-refractory CIS of the bladder who are not good surgical candidates. Randomised studies of intravesical valrubicin for the treatment of superficial bladder cancer are ongoing.

Author List

Kuznetsov DD, Alsikafi NF, O'Connor RC, Steinberg GD

Author

Robert Corey O'Connor MD Professor in the Urologic Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Administration, Intravesical
Antineoplastic Agents
Carcinoma in Situ
Carcinoma, Transitional Cell
Clinical Trials as Topic
Doxorubicin
Guidelines as Topic
Humans
Molecular Structure
Urinary Bladder Neoplasms